Clinical Trial Update: INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial investigating QL1706 in combination with bevacizumab for advanced first-line ovarian clear cell carcinoma; the study is not yet recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Clear Cell Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• QL1706

Snippet

Sponsor: Tongji Hospital | Conditions: Ovarian Clear Cell Carcinoma | Phase 3 | Status: NOT_YET_RECRUITING